Effects of denosumab on hypercalcemia and bone mineral density loss in kidney transplant recipients 
.

CONCLUSION: Denosumab could improve hypercalcemia and BMD loss in kidney transplant recipients. Therapeutic intervention involving denosumab should be considered for hypercalcemia and BMD loss associated with post-transplant chronic kidney disease-mineral and bone disorder.
.
PMID: 30990412 [PubMed - as supplied by publisher]

Source: Clinical Nephrology - April 15, 2019 Category: Urology & Nephrology Authors: Nanmoku K, Shinzato T, Kubo T, Shimizu T, Yagisawa T Tags: Clin Nephrol Source Type: research